{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121827","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.380867+00:00","generated_at":"2026-05-30T04:52:25.438256+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NewAmsterdam Pharma Q3 net loss $16.6M; Phase 3 TANDEM topline expected Q4 2024","bullets":["Cash $422.7M as of Sep 30, 2024, up from $340.5M at Dec 31, 2023.","Revenue $29.1M in Q3 2024 from Menarini milestone; net loss $16.6M vs $47.1M in Q3 2023.","Phase 3 TANDEM topline data now expected in Q4 2024 due to faster enrollment.","On track for BROADWAY topline data in Q4 2024; BROOKLYN data at AHA Nov 16-18."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121827","json":"https://secwatch.observer/filing/0000950170-24-121827.json","markdown":"https://secwatch.observer/filing/0000950170-24-121827.md","text":"https://secwatch.observer/filing/0000950170-24-121827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024121827/0000950170-24-121827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024121827/nams-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:52:25.438256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}